| 1 |
32194638 | A Novel Heterozygous Variant in F2 Gene in a Chinese Patient With Coronary Thrombosis and Acute Myocardial Infarction Leads to Antithrombin Resistance. | 2020 |
1 |
| 2 |
26797521 | The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa. | 2016 Feb 12 |
1 |
| 3 |
27010094 | Cerebral venous sinus thrombosis in the patient with multiple sclerosis associated with congenital antithrombin deficiency. | 2016 Apr 28 |
1 |
| 4 |
25307422 | The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III. | 2014 Dec |
1 |
| 5 |
23578459 | [Molecular mechanisms of antithrombin deficiency caused by novel double heterozygous mutations]. | 2013 Jan 1 |
8 |
| 6 |
23581397 | A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. | 2013 Jun |
1 |
| 7 |
21875153 | Energetics of hydrogen bond switch, residue burial and cavity analysis reveals molecular basis of improved heparin binding to antithrombin. | 2011 Oct |
2 |
| 8 |
19010776 | Engineering functional antithrombin exosites in alpha1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa. | 2009 Jan 16 |
1 |
| 9 |
19172319 | A computational modeling and molecular dynamics study of the Michaelis complex of human protein Z-dependent protease inhibitor (ZPI) and factor Xa (FXa). | 2009 Aug |
1 |
| 10 |
19689280 | Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure. | 2009 |
3 |
| 11 |
19818773 | Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement. | 2009 Nov 3 |
1 |
| 12 |
19843180 | Effect of citrullination on the function and conformation of antithrombin. | 2009 Nov |
1 |
| 13 |
12591924 | Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. | 2003 Apr 18 |
3 |
| 14 |
12846563 | Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. | 2003 Jul 15 |
1 |
| 15 |
12939144 | Introduction of a mutation in the shutter region of antithrombin (Phe77 --> Leu) increases affinity for heparin and decreases thermal stability. | 2003 Sep 2 |
2 |
| 16 |
11971909 | Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition. | 2002 Jul 5 |
1 |
| 17 |
12022882 | Role of basic residues of the autolysis loop in the catalytic function of factor Xa. | 2002 May 28 |
3 |
| 18 |
12161073 | Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants. | 2002 Jul |
1 |
| 19 |
12369826 | Specificity of the basic side chains of Lys114, Lys125, and Arg129 of antithrombin in heparin binding. | 2002 Oct 15 |
3 |
| 20 |
11380262 | The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation. | 2001 Jun 5 |
5 |
| 21 |
11389017 | Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion. | 2001 Jun 15 |
2 |
| 22 |
10764763 | Role of arginine 129 in heparin binding and activation of antithrombin. | 2000 Jun 23 |
4 |
| 23 |
9235938 | Identification of the antithrombin III heparin binding site. | 1997 Aug 1 |
5 |
| 24 |
9242619 | Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. | 1997 Aug 8 |
8 |
| 25 |
8900394 | Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes. | 1996 Oct 15 |
1 |
| 26 |
8910598 | Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin. | 1996 Nov 15 |
1 |
| 27 |
7893664 | Inhibition of acrosin by serpins. A suicide substrate mechanism. | 1995 Mar 21 |
1 |
| 28 |
7981186 | Three novel mutations of antithrombin inducing high-molecular-mass compounds. | 1994 Dec |
2 |
| 29 |
8186357 | An overview of the mechanism of action of antithrombin and its inherited deficiency states. | 1994 Jan |
1 |
| 30 |
8280781 | Arg-129 plays a specific role in the conformation of antithrombin and in the enhancement of factor Xa inhibition by the pentasaccharide sequence of heparin. | 1994 Jan 11 |
1 |
| 31 |
8331659 | Crystal structure of cleaved bovine antithrombin III at 3.2 A resolution. | 1993 Jul 5 |
1 |
| 32 |
8392392 | General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor. | 1993 Jun |
1 |
| 33 |
1331047 | The role of the COOH-terminal region of antithrombin III. Evidence that the COOH-terminal region of the inhibitor enhances the reactivity of thrombin and factor Xa with the inhibitor. | 1992 Nov 5 |
1 |
| 34 |
1569192 | Met 358 to Arg mutation of alpha 1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency. | 1992 May |
1 |
| 35 |
1776135 | Congenital antithrombin III deficiency (AT-III Kyoto): identification of a point mutation altering arginine-406 to methionine behind the reactive site. | 1991 Oct 1 |
1 |
| 36 |
1870264 | [Clinical and genetic aspects of antithrombin III deficiency and abnormal antithrombin III]. | 1991 May |
1 |
| 37 |
2229057 | Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine. | 1990 Nov 5 |
5 |
| 38 |
2394749 | A retinoic acid-inducible mRNA from F9 teratocarcinoma cells encodes a novel protease inhibitor homologue. | 1990 Sep 15 |
1 |
| 39 |
3191114 | Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. | 1988 Aug 9 |
1 |
| 40 |
3260695 | Thrombin binding properties of insoluble modified polystyrene: Part II. | 1988 Apr 15 |
2 |
| 41 |
3305015 | Probing the heparin-binding domain of human antithrombin III with V8 protease. | 1987 Sep 1 |
1 |
| 42 |
3603738 | [Antithrombin activity of methyl esters of arginine-containing peptides]. | 1987 May-Jun |
1 |
| 43 |
3000827 | The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III. | 1986 Jan 6 |
3 |
| 44 |
3080419 | Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. | 1986 Jan 25 |
1 |
| 45 |
3754413 | Structure-function relationships in heparin cofactor II: chemical modification of arginine and tryptophan and demonstration of a two-domain structure. | 1986 Apr |
1 |
| 46 |
3863104 | Inhibition of chymotrypsin by heparin cofactor II. | 1985 Oct |
1 |
| 47 |
6582486 | Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. | 1984 Jan |
2 |
| 48 |
6338832 | Formation and stability of the complex formed between human antithrombin-III and thrombin. | 1983 Jan |
2 |
| 49 |
6977539 | The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. | 1982 Mar 10 |
2 |
| 50 |
6790279 | Immunological evidence for a proteolytic cleavage at the active site of antithrombin in the mechanism of inhibition of coagulation serine proteases. | 1981 Jun 1 |
1 |